Ivermectin and COVID 19
Ivermectin
https://bnf.nice.org.uk/drug/ivermectin.html#indicationsAndDoses
Invitro antiviral activity
Against a broad range of viruses
HIV, dengue, influenza, Zika virus
Invitro antiviral, SARS-CoV-2 activity
99.8% reduction in viral RNA after 48 h
Worldwide use for treating COVID-19
About 3.7 billion doses of ivermectin have been distributed globally over the past 30 years
EVMS CRITICAL CARE COVID-19 MANAGEMENT PROTOCOL
https://www.evms.edu/media/evms_public/departments/internal_medicine/EVMS_Critical_Care_COVID-19_Protocol.pdf
Preexposure prophylaxis in high-risk patients
Postexposure prophylaxis
Symptomatic patients at home
Mildly symptomatic patients in hospital
Progressive Respiratory symptoms
Ivermectin has emerged as the “wonder drug” to prophylaxis and treat COVID-19
Ivermectin inhibits viral replication and has potent anti-inflammatory properties
There is the potential for serious drug-drug interaction
Additional, studies are urgently required to confirm these very impressive preliminary findings
Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 (7th December)
https://covid19criticalcare.com/wp-content/uploads/2020/11/FLCCC-Ivermectin-in-the-prophylaxis-and-treatment-of-COVID-19.pdf
Front Line COVID-19 Critical Care Alliance (FLCCC)
One Sentence Summary
Review of recently available clinical trial results demonstrating efficacy of ivermectin in prophylaxis and treatment of COVID-19.
Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019
The ICON Study (October 2020, South Florida)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550891/
Research Question
Does ivermectin benefit hospitalized coronavirus disease 2019 (COVID-19) patients?
Study Design and Methods
Consecutive patients hospitalized
Four hospitals in Florida
Confirmed COVID-19
March 15 and May 11, 2020
Treated with or without ivermectin
Primary outcome
All-cause in-hospital mortality
Secondary outcomes, mortality in patients with severe pulmonary involvement, extubation rates for mechanically ventilated patients, length of stay
Severe pulmonary involvement
Need for Fio2 ≥ 50%, noninvasive ventilation
Invasive ventilation
Results from reviews
N = 280
Ivermectin treated = 173
Overall mortality 15%
Mortality with severe pulmonary involvement = 38.8%
Not given ivermectin = 107
Overall mortality 25% (OR, 0.52)
Mortality with severe pulmonary involvement = 80.7%
No significant differences were found in extubation rates or length of stay
Most patients in both groups also received hydroxychloroquine, azithromycin, or both
Interpretation
Ivermectin treatment was associated with lower mortality during treatment of COVID-19
Especially in patients with severe pulmonary involvement
Randomized controlled trials are needed to confirm these findings
Ivermectin news
https://www.newswise.com/coronavirus/flccc-alliance-calls-on-national-health-authorities-to-immediately-review-medical-evidence-showing-the-efficacy-of-ivermectin-for-the-prevention-of-covid-19-and-as-an-early-outpatient-treatment
Видео Ivermectin and COVID 19 канала Dr. John Campbell
https://bnf.nice.org.uk/drug/ivermectin.html#indicationsAndDoses
Invitro antiviral activity
Against a broad range of viruses
HIV, dengue, influenza, Zika virus
Invitro antiviral, SARS-CoV-2 activity
99.8% reduction in viral RNA after 48 h
Worldwide use for treating COVID-19
About 3.7 billion doses of ivermectin have been distributed globally over the past 30 years
EVMS CRITICAL CARE COVID-19 MANAGEMENT PROTOCOL
https://www.evms.edu/media/evms_public/departments/internal_medicine/EVMS_Critical_Care_COVID-19_Protocol.pdf
Preexposure prophylaxis in high-risk patients
Postexposure prophylaxis
Symptomatic patients at home
Mildly symptomatic patients in hospital
Progressive Respiratory symptoms
Ivermectin has emerged as the “wonder drug” to prophylaxis and treat COVID-19
Ivermectin inhibits viral replication and has potent anti-inflammatory properties
There is the potential for serious drug-drug interaction
Additional, studies are urgently required to confirm these very impressive preliminary findings
Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 (7th December)
https://covid19criticalcare.com/wp-content/uploads/2020/11/FLCCC-Ivermectin-in-the-prophylaxis-and-treatment-of-COVID-19.pdf
Front Line COVID-19 Critical Care Alliance (FLCCC)
One Sentence Summary
Review of recently available clinical trial results demonstrating efficacy of ivermectin in prophylaxis and treatment of COVID-19.
Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019
The ICON Study (October 2020, South Florida)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550891/
Research Question
Does ivermectin benefit hospitalized coronavirus disease 2019 (COVID-19) patients?
Study Design and Methods
Consecutive patients hospitalized
Four hospitals in Florida
Confirmed COVID-19
March 15 and May 11, 2020
Treated with or without ivermectin
Primary outcome
All-cause in-hospital mortality
Secondary outcomes, mortality in patients with severe pulmonary involvement, extubation rates for mechanically ventilated patients, length of stay
Severe pulmonary involvement
Need for Fio2 ≥ 50%, noninvasive ventilation
Invasive ventilation
Results from reviews
N = 280
Ivermectin treated = 173
Overall mortality 15%
Mortality with severe pulmonary involvement = 38.8%
Not given ivermectin = 107
Overall mortality 25% (OR, 0.52)
Mortality with severe pulmonary involvement = 80.7%
No significant differences were found in extubation rates or length of stay
Most patients in both groups also received hydroxychloroquine, azithromycin, or both
Interpretation
Ivermectin treatment was associated with lower mortality during treatment of COVID-19
Especially in patients with severe pulmonary involvement
Randomized controlled trials are needed to confirm these findings
Ivermectin news
https://www.newswise.com/coronavirus/flccc-alliance-calls-on-national-health-authorities-to-immediately-review-medical-evidence-showing-the-efficacy-of-ivermectin-for-the-prevention-of-covid-19-and-as-an-early-outpatient-treatment
Видео Ivermectin and COVID 19 канала Dr. John Campbell
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Theraputic mouth wash, allergies and stomach acidWeekend updateHow Big Can Wind Turbines Get?PREVENTING COVID-19: Dr. Pierre Kory Pushes for Approval of Ivermectin Treatment For Covid-19Thursday Pandemic UpdateLong term immunity, looking goodCoronavirus Update 117: Moderna vs. Pfizer COVID 19 Vaccine (mRNA vaccines)Dr. Pierre Kory Talks Covid-19, Ivermectin and the FLCCC | Podcast E43Oestrogen and COVID severity in womenCroatia, special reportIvermectin Alone More Effective Than Ivermectin and DoxycyclineCanadian Pandemic with LindsayFirst peer-reviewed vaccine evidenceFirst reported COVID reinfectionBeyond The Roundup | Senate Committee Hearing On Ivermectin Brings Unexpected DramaVaccine, game changerStudy - Honey and Nigella Sativa For COVID-19First Vaccine approved in UKPandemic, winter worriesHIDDEN MATHEMATICS - Randall Carlson - Ancient Knowledge of Space, Time & Cosmic Cycles